Mutations in muscle-type creatine kinase impact HIV prevention.

There is large interindividual variability in the efficacy of pre-exposure prophylaxis (PrEP) with tenofovir (TFV) in preventing HIV infection. Naturally occurring mutations in the creatine kinase M-type (CKM) gene examined by Mosher et al. could provide answers to why some individuals who have active serum creatine kinase in clinical assessments may not respond to TFV PrEP.